

Pasquale Pignatelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3480266/publications.pdf>

Version: 2024-02-01

313
papers

11,400
citations

24978

57
h-index

46693

89
g-index

319
all docs

319
docs citations

319
times ranked

13224
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2023, 20, 24-37.	6.1	67
2	Corticosteroid use, myocardial injury and in-hospital cardiovascular events in patients with community-acquired pneumonia. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 155-165.	1.1	6
3	Toll-like receptor 4 activation in platelets from myocardial infarction patients. <i>Thrombosis Research</i> , 2022, 209, 33-40.	0.8	8
4	Interventional study with vitamin E in cardiovascular disease and meta-analysis. <i>Free Radical Biology and Medicine</i> , 2022, 178, 26-41.	1.3	32
5	Comparison of Thrombotic Events and Mortality in Patients with Community-Acquired Pneumonia and COVID-19: A Multicenter Observational Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 257-266.	1.8	18
6	Cardiac and vascular features of arterial and venous primary antiphospholipid syndrome. The multicenter ATHERO-APS study. <i>Thrombosis Research</i> , 2022, 209, 69-74.	0.8	8
7	A Meta-Analysis of Plasma Homocysteine in Buerger's Disease. <i>Thrombosis and Haemostasis</i> , 2022, , .	1.8	0
8	Bleeding and mortality risk in patients implanted with mechanical prosthetic heart valves with and without thrombocytopenia. Insights from the nationwide PLECTRUM registry. <i>Platelets</i> , 2022, , 1-6.	1.1	0
9	Reply to Chen and Vitetta. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00448.	1.3	0
10	The ADA (Age-D-Dimer-Albumin) Score to Predict Thrombosis in SARS-CoV-2. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1567-1572.	1.8	11
11	Full <i>versus</i> prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis. <i>Haematologica</i> , 2022, 107, 1933-1939.	1.7	5
12	Testosterone-to-estradiol ratio and platelet thromboxane release in ischemic heart disease: the EVA project. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1367-1377.	1.8	7
13	Mediterranean Diet: A Tool to Break the Relationship of Atrial Fibrillation with the Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2022, 14, 1260.	1.7	10
14	Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis. <i>Antioxidants</i> , 2022, 11, 569.	2.2	8
15	High Compliance to Mediterranean Diet Associates with Lower Platelet Activation and Liver Collagen Deposition in Patients with Nonalcoholic Fatty Liver Disease. <i>Nutrients</i> , 2022, 14, 1209.	1.7	5
16	Safety of the oral factor Xla inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. <i>Lancet, The</i> , 2022, 399, 1383-1390.	6.3	131
17	Platelet Activation Favours NOX2-Mediated Muscle Damage in Elite Athletes: The Role of Cocoa-Derived Polyphenols. <i>Nutrients</i> , 2022, 14, 1558.	1.7	4
18	Aging-Related Decline of Autophagy in Patients with Atrial Fibrillation”A Post Hoc Analysis of the ATHERO-AF Study. <i>Antioxidants</i> , 2022, 11, 698.	2.2	5

#	ARTICLE	IF	CITATIONS
19	Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study. <i>Journal of Autoimmunity</i> , 2022, 129, 102832.	3.0	3
20	Clinical Phenotypes of Atrial Fibrillation and Mortality Risk—A Cluster Analysis from the Nationwide Italian START Registry. <i>Journal of Personalized Medicine</i> , 2022, 12, 785.	1.1	4
21	Extra Virgin Olive Oil Reduces Gut Permeability and Metabolic Endotoxemia in Diabetic Patients. <i>Nutrients</i> , 2022, 14, 2153.	1.7	11
22	Thromboembolic Complications in COVID-19 Patients Hospitalized in Italian Ordinary Wards: Data from the Multicenter Observational START-COVID Register. <i>TH Open</i> , 2022, 06, e251-e256.	0.7	2
23	Is Albumin Predictor of Mortality in COVID-19?. <i>Antioxidants and Redox Signaling</i> , 2021, 35, 139-142.	2.5	136
24	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 379-387.	1.0	21
25	Update and Unmet Needs on the Use of Nonvitamin K Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation. <i>Current Problems in Cardiology</i> , 2021, 46, 100410.	1.1	7
26	T2238C atrial natriuretic peptide gene variant and cardiovascular events in patients with atrial fibrillation: A substudy from the ATHERO-AF cohort. <i>International Journal of Cardiology</i> , 2021, 322, 245-249.	0.8	1
27	Atrial fibrillation pattern, left atrial diameter and risk of cardiovascular events and mortality. A prospective multicenter cohort study. <i>International Journal of Clinical Practice</i> , 2021, 75, e13771.	0.8	14
28	Relation of Atrial Fibrillation to Angiographic Characteristics and Coronary Artery Disease Severity in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2021, 141, 1-6.	0.7	5
29	Long-Term Risk of Major Adverse Cardiac Events in Atrial Fibrillation Patients on Direct Oral Anticoagulants. <i>Mayo Clinic Proceedings</i> , 2021, 96, 658-665.	1.4	22
30	Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry. <i>International Journal of Cardiology</i> , 2021, 327, 176-182.	0.8	10
31	Direct oral anticoagulants and advanced liver disease: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13397.	1.7	21
32	Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605,771 patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f11-f19.	1.4	40
33	Sex-based difference in anticoagulated patients with mechanical prosthetic heart valves and long-term mortality risk. <i>International Journal of Clinical Practice</i> , 2021, 75, e14064.	0.8	1
34	Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. <i>Internal and Emergency Medicine</i> , 2021, 16, 1583-1591.	1.0	9
35	The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study. <i>European Journal of Internal Medicine</i> , 2021, 85, 80-85.	1.0	21
36	Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study. <i>Internal and Emergency Medicine</i> , 2021, 16, 2063-2068.	1.0	5

#	ARTICLE	IF	CITATIONS
37	Comparison of Anticoagulation Quality between Acenocoumarol and Warfarin in Patients with Mechanical Prosthetic Heart Valves: Insights from the Nationwide PLECTRUM Study. <i>Molecules</i> , 2021, 26, 1425.	1.7	12
38	Statin use and mortality in atrial fibrillation: A systematic review and meta-analysis of 100,287 patients. <i>Pharmacological Research</i> , 2021, 165, 105418.	3.1	21
39	Serum albumin, clotting activation and COVID-19 severity: a systematic review and meta-regression analysis of 4579 patients. <i>Italian Journal of Emergency Medicine</i> , 2021, 10, .	0.0	3
40	Beneficial effects of a combination of natural product activators of autophagy on endothelial cells and platelets. <i>British Journal of Pharmacology</i> , 2021, 178, 2146-2159.	2.7	15
41	Nox2 up-regulation and hypoalbuminemia in patients with type 2 diabetes mellitus. <i>Free Radical Biology and Medicine</i> , 2021, 168, 1-5.	1.3	5
42	Cancer and atrial fibrillation: Epidemiology, mechanisms, and anticoagulation treatment. <i>Progress in Cardiovascular Diseases</i> , 2021, 66, 28-36.	1.6	25
43	Isoprostanes in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2021, 20, 102821.	2.5	5
44	Low-Grade Endotoxemia and Thrombosis in COVID-19. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00348.	1.3	32
45	Impaired Clinical Efficacy of Aspirin in Hypoalbuminemic Patients With Diabetes Mellitus. <i>Frontiers in Pharmacology</i> , 2021, 12, 695961.	1.6	8
46	Thrombosis in Covid-19 and non-Covid-19 pneumonia: role of platelets. <i>Platelets</i> , 2021, 32, 1009-1017.	1.1	12
47	Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7193.	1.8	26
48	Antiphospholipid Antibodies and Heart Failure with Preserved Ejection Fraction. The Multicenter ATHERO-APS Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3180.	1.0	9
49	Arterial and venous thrombosis in coronavirus 2019 disease (Covid-19): relationship with mortality. <i>Internal and Emergency Medicine</i> , 2021, 16, 1231-1237.	1.0	20
50	Predictors of Renal Function Worsening in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Multicenter Observational Study. <i>Nutrients</i> , 2021, 13, 2811.	1.7	13
51	Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 715878.	1.1	39
52	Low serum albumin levels and in-hospital outcomes in patients with ST segment elevation myocardial infarction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2904-2911.	1.1	33
53	Lipopolysaccharide induces platelet activation in HIV patients: the role of different viral load patterns. <i>HIV Medicine</i> , 2021, 22, 434-444.	1.0	4
54	Albumin Supplementation Dampens Hypercoagulability in COVID-19: A Preliminary Report. <i>Thrombosis and Haemostasis</i> , 2021, 121, 102-105.	1.8	36

#	ARTICLE	IF	CITATIONS
55	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. <i>International Journal of Cardiology</i> , 2021, 345, 7-13.	0.8	35
56	Thrombosis in pre- and post-vaccination phase of COVID-19. <i>European Heart Journal Supplements</i> , 2021, 23, E184-E188.	0.0	5
57	Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 779503.	1.1	8
58	D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: a systematic review and meta-analysis. <i>Thrombosis Journal</i> , 2021, 19, 102.	0.9	10
59	Serum albumin and risk of cardiovascular events in primary and secondary prevention: a systematic review of observational studies and Bayesian meta-regression analysis. <i>Internal and Emergency Medicine</i> , 2020, 15, 135-143.	1.0	21
60	Prevalence and Impact of Nonalcoholic Fatty Liver Disease in Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2020, 95, 513-520.	1.4	11
61	Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry. <i>Angiology</i> , 2020, 71, 235-241.	0.8	3
62	Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962094579.	0.7	8
63	Family History of Atrial Fibrillation and Risk of Cardiovascular Events. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008477.	2.1	3
64	Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?. <i>Drugs</i> , 2020, 80, 1383-1396.	4.9	93
65	Nox2 activation in Covid-19. <i>Redox Biology</i> , 2020, 36, 101655.	3.9	114
66	Antiphospholipid antibodies and lower extremity peripheral artery disease: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1291-1298.	1.6	15
67	Features of severe COVID-19: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13378.	1.7	141
68	Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2455-2463.	1.1	24
69	Nutrition, Thrombosis, and Cardiovascular Disease. <i>Circulation Research</i> , 2020, 126, 1415-1442.	2.0	35
70	Letter by Violi et al Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of Fxa-Driven Platelet Activation via Protease Activated Receptor-1". <i>Circulation Research</i> , 2020, 126, e114-e115.	2.0	1
71	SARS-CoV-2 and myocardial injury: a role for Nox2?. <i>Internal and Emergency Medicine</i> , 2020, 15, 755-758.	1.0	18
72	Antiphospholipid antibodies in <sc>end</sc> renal disease: A systematic review and <sc>meta</sc>. <i>Hemodialysis International</i> , 2020, 24, 383-396.	0.4	4

#	ARTICLE	IF	CITATIONS
73	Antiphospholipid Antibodies and Autoimmune Haemolytic Anaemia: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4120.	1.8	13
74	Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs. <i>European Journal of Internal Medicine</i> , 2020, 80, 73-77.	1.0	7
75	Hypoalbuminemia, Coagulopathy, and Vascular Disease in COVID-19. <i>Circulation Research</i> , 2020, 127, 400-401.	2.0	60
76	Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management. <i>Haematologica</i> , 2020, 105, 562-572.	1.7	81
77	Cancer-specific ischemic complications in elderly patients with atrial fibrillation: Data from the prospective AThERO-AF study. <i>International Journal of Cancer</i> , 2020, 147, 3424-3430.	2.3	8
78	Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced Liver Disease: An Exploratory Meta-Analysis. <i>Hepatology Communications</i> , 2020, 4, 1034-1040.	2.0	22
79	Determinants of low-quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study. <i>British Journal of Haematology</i> , 2020, 190, 588-593.	1.2	14
80	Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge. <i>Thrombosis and Haemostasis</i> , 2020, 120, 949-956.	1.8	183
81	A novel role of MMP2 in regulating platelet NOX2 activation. <i>Free Radical Biology and Medicine</i> , 2020, 152, 355-362.	1.3	15
82	PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation. <i>Antioxidants</i> , 2020, 9, 296.	2.2	28
83	Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 355-360.	1.0	16
84	Integrated care management of patients with atrial fibrillation "far from optimal. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 176-178.	0.3	0
85	Paroxysmal nocturnal hemoglobinuria and cardio-respiratory system: new pathophysiological evidences. , 2020, , .		0
86	Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry. <i>Angiology</i> , 2019, 70, 257-263.	0.8	21
87	Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry. <i>PLoS ONE</i> , 2019, 14, e0219676.	1.1	16
88	Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation: A post-hoc analysis from the AThERO-AF cohort. <i>Atherosclerosis</i> , 2019, 289, 195-200.	0.4	12
89	Does the Coexistence of Chronic Obstructive Pulmonary Disease and Atrial Fibrillation Affect Nox2 Activity and Urinary Isoprostanes Excretion?. <i>Antioxidants and Redox Signaling</i> , 2019, 31, 786-790.	2.5	4
90	Anticoagulants in Atrial Fibrillation and Liver Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2436.	1.2	0

#	ARTICLE	IF	CITATIONS
91	Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e012596.	1.6	23
92	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , 2019, 124, 1662-1668.	0.7	20
93	Left Atrium Dilatation and Left Ventricular Hypertrophy Predispose to Atrial Fibrillation in Patients With Community-Acquired Pneumonia. <i>American Journal of Cardiology</i> , 2019, 124, 723-728.	0.7	11
94	Alirocumab after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2019, 380, 2074-2077.	13.9	2
95	Relationship of Antiphospholipid Antibodies to Risk of Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 561-576.	1.2	20
96	Acute Effects of Heat-Not-Burn, Electronic Vaping, and Traditional Tobacco Combustion Cigarettes: The Sapienza University of Rome Vascular Assessment of Proatherosclerotic Effects of Smoking (SURVAPES) 2 Randomized Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e010455.	1.6	112
97	Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 519-525.	2.5	28
98	The Sex-Specific Detrimental Effect of Diabetes and Gender-Related Factors on Pre-admission Medication Adherence Among Patients Hospitalized for Ischemic Heart Disease: Insights From EVA Study. <i>Frontiers in Endocrinology</i> , 2019, 10, 107.	1.5	6
99	Tailored Practical Management of Patients With Atrial Fibrillation: A Risk Factor-Based Approach. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 17.	1.1	8
100	Nox2-mediated platelet activation by glycoprotein (GP) VI: Effect of rivaroxaban alone and in combination with aspirin. <i>Biochemical Pharmacology</i> , 2019, 163, 111-118.	2.0	16
101	Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 508-515.	1.1	19
102	Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1261-1267.	1.4	89
103	ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study. <i>American Journal of Medicine</i> , 2019, 132, 856-861.	0.6	67
104	Low Rate of Intrahospital Deep Venous Thrombosis in Acutely Ill Medical Patients: Results From the AURELIO Study. <i>Mayo Clinic Proceedings</i> , 2019, 94, 37-43.	1.4	17
105	Silybin and metabolic disorders. <i>Internal and Emergency Medicine</i> , 2019, 14, 1-3.	1.0	7
106	Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer. <i>Internal and Emergency Medicine</i> , 2019, 14, 21-38.	1.0	13
107	Multiple Arterial Thrombosis in Seronegative Antiphospholipid Syndrome: Need for New Diagnostic Criteria?. <i>European Journal of Case Reports in Internal Medicine</i> , 2019, 6, 1.	0.2	1
108	Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2018, 54, 34-39.	1.0	18

#	ARTICLE	IF	CITATIONS
109	Reply. Journal of the American College of Cardiology, 2018, 71, 706-707.	1.2	0
110	Relationship of peripheral and coronary artery disease to cardiovascular events in patients with atrial fibrillation. International Journal of Cardiology, 2018, 255, 69-73.	0.8	21
111	Blood hydrogen peroxide break-down activity in healthy subjects and in patients at risk of cardiovascular events. Atherosclerosis, 2018, 274, 29-34.	0.4	13
112	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. Internal and Emergency Medicine, 2018, 13, 651-660.	1.0	29
113	Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naïve patients with atrial fibrillation. American Heart Journal, 2018, 200, 32-36.	1.2	13
114	Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry. Angiology, 2018, 69, 795-802.	0.8	35
115	Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. Data in Brief, 2018, 17, 830-836.	0.5	5
116	Ageing and Adherence to the Mediterranean Diet: Relationship with Cardiometabolic Disorders and Polypharmacy. Journal of Nutrition, Health and Aging, 2018, 22, 73-81.	1.5	13
117	Early decrease of oxidative stress by non-invasive ventilation in patients with acute respiratory failure. Internal and Emergency Medicine, 2018, 13, 183-190.	1.0	9
118	Risk of reoperation in bioprosthetic valve patients with indication for long-term anticoagulation. Results from the observational retrospective multicentre PLECTRUM study. Open Heart, 2018, 5, e000837.	0.9	6
119	Digoxin and Platelet Activation in Patients With Atrial Fibrillation: In Vivo and In Vitro Study. Journal of the American Heart Association, 2018, 7, e009509.	1.6	9
120	Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. International Journal of Cardiology, 2018, 264, 58-63.	0.8	69
121	Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry). American Journal of Cardiology, 2018, 122, 936-943.	0.7	12
122	Impact of Tobacco Versus Electronic Cigarette Smoking on Platelet Function. American Journal of Cardiology, 2018, 122, 1477-1481.	0.7	65
123	Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. Circulation Journal, 2018, 82, 1286-1292.	0.7	4
124	Oxidative stress and cardiovascular disease: new insights. Kardiologia Polska, 2018, 76, 713-722.	0.3	150
125	Abstract 529: Digoxin and Platelet Activation in Atrial fibrillation Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, .	1.1	0
126	Abstract 360: Rivaroxaban Enhances the Antiplatelet Activity of Aspirin via Inhibition of Nox2-mediated Thromboxane A 2 and Isoprostane Biosynthesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, .	1.1	0

#	ARTICLE	IF	CITATIONS
127	Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. <i>International Journal of Cardiology</i> , 2017, 231, 143-149.	0.8	22
128	Italian intersociety consensus on DOAC use in internal medicine. <i>Internal and Emergency Medicine</i> , 2017, 12, 387-406.	1.0	44
129	C2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP. <i>Scientific Reports</i> , 2017, 7, 3797.	1.6	8
130	Gut-Derived Serum Lipopolysaccharide is Associated With Enhanced Risk of Major Adverse Cardiovascular Events in Atrial Fibrillation: Effect of Adherence to Mediterranean Diet. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	105
131	Assessment of risk factors for candidemia in non-neutropenic patients hospitalized in Internal Medicine wards: A multicenter study. <i>European Journal of Internal Medicine</i> , 2017, 41, 33-38.	1.0	35
132	Reply to: Monitoring antithrombotic therapy in antiphospholipid syndrome: A challenge in quality. <i>Atherosclerosis</i> , 2017, 256, 148-149.	0.4	0
133	NADPH Oxidase-2 and Atherothrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 218-225.	1.1	84
134	Atherothrombosis and Oxidative Stress: Mechanisms and Management in Elderly. <i>Antioxidants and Redox Signaling</i> , 2017, 27, 1083-1124.	2.5	92
135	Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1455-1462.	1.2	57
136	Lipopolysaccharide as trigger of platelet aggregation via eicosanoid over-production. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1558-1570.	1.8	56
137	Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. <i>PLoS ONE</i> , 2017, 12, e0186961.	1.1	21
138	NOX 5 is expressed in platelets from patients with chronic granulomatous disease. <i>Thrombosis and Haemostasis</i> , 2016, 116, 198-200.	1.8	8
139	Ankle-Brachial Index and cardiovascular events in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 856-863.	1.8	30
140	Short-term in vivo modifications of platelet NADPH oxidase 2 (NOX2) and prostaglandin F ₂ in HIV-1 patients on abacavir-based therapies. <i>HIV Medicine</i> , 2016, 17, 774-777.	1.0	0
141	Identification of Different Patterns of Dabigatran In Vivo Bioactivation in Patients on Maintenance Anticoagulation Therapy. <i>Thrombosis and Haemostasis</i> , 2016, 38, 814-816.	1.0	0
142	Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	143
143	Enhanced Soluble Serum CD40L and Serum P-Selectin Levels in Primary Aldosteronism. <i>Hormone and Metabolic Research</i> , 2016, 48, 440-445.	0.7	13
144	Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding. <i>Pharmacological Research</i> , 2016, 113, 484-489.	3.1	22

#	ARTICLE	IF	CITATIONS
145	Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , 2016, 223, 619-624.	0.8	11
146	Is There an Interplay Between Adherence to Mediterranean Diet, Antioxidant Status, and Vascular Disease in Atrial Fibrillation Patients?. <i>Antioxidants and Redox Signaling</i> , 2016, 25, 751-755.	2.5	15
147	Impaired flow-mediated dilation in hospitalized patients with community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2016, 36, 74-80.	1.0	15
148	Aging-Related Decline of Glutathione Peroxidase 3 and Risk of Cardiovascular Events in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	51
149	Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia. <i>Journal of Infection</i> , 2016, 73, 107-114.	1.7	45
150	Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists. <i>Medicine (United States)</i> , 2016, 95, e2895.	0.4	50
151	Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma. <i>Bioanalysis</i> , 2016, 8, 275-283.	0.6	36
152	Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. <i>Internal and Emergency Medicine</i> , 2016, 11, 199-204.	1.0	41
153	Reply to: "Inadequate anticoagulation by vitamin K antagonists and major adverse cardiovascular events other than stroke". <i>International Journal of Cardiology</i> , 2016, 202, 934-935.	0.8	0
154	Antiphospholipid syndrome and anticoagulation quality: a clinical challenge. <i>Atherosclerosis</i> , 2016, 244, 48-50.	0.4	14
155	Age-related increase of thromboxane B2 and risk of cardiovascular disease in atrial fibrillation. <i>Oncotarget</i> , 2016, 7, 39143-39147.	0.8	18
156	Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk/benefit profile to personalised treatment. <i>Thrombosis and Haemostasis</i> , 2015, 114, 876-882.	1.8	17
157	Serum NOX2 and urinary isoprostanes predict vascular events in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2015, 113, 617-624.	1.8	50
158	Incidence of Myocardial Infarction and Vascular Death in Elderly Patients With Atrial Fibrillation Taking Anticoagulants. <i>Chest</i> , 2015, 147, 1644-1650.	0.4	59
159	HIV-1 induces in vivo platelet activation by enhancing platelet NOX2 activity. <i>Journal of Infection</i> , 2015, 70, 651-658.	1.7	17
160	Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study. <i>BMJ Open</i> , 2015, 5, e008026-e008026.	0.8	21
161	Relation of Cardiac Complications in the Early Phase of Community-Acquired Pneumonia to Long-Term Mortality and Cardiovascular Events. <i>American Journal of Cardiology</i> , 2015, 116, 647-651.	0.7	110
162	Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists. <i>Europace</i> , 2015, 17, 1223-1228.	0.7	13

#	ARTICLE	IF	CITATIONS
163	Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation. <i>American Heart Journal</i> , 2015, 170, 490-497.e1.	1.2	26
164	Nox2 up-regulation is associated with an enhanced risk of atrial fibrillation in patients with pneumonia. <i>Thorax</i> , 2015, 70, 961-966.	2.7	38
165	Lights and shadows in the management of old and new oral anticoagulants in the real world of atrial fibrillation by Italian internists. A survey from the Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study. <i>European Journal of Internal Medicine</i> , 2015, 26, e31-e33.	1.0	2
166	Extra virgin olive oil use is associated with improved post-prandial blood glucose and LDL cholesterol in healthy subjects. <i>Nutrition and Diabetes</i> , 2015, 5, e172-e172.	1.5	74
167	Response to Digoxin or digoxin prescribed patient? Randomized trials are essential to discriminate the principal risk factor for the association of digoxin and increased mortality. <i>International Journal of Cardiology</i> , 2015, 189, 247-248.	0.8	0
168	Does Mediterranean Diet Reduce Cardiovascular Events and Oxidative Stress in Atrial Fibrillation?. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 682-687.	2.5	49
169	Nox-2 up-regulation and platelet activation: Novel insights. <i>Prostaglandins and Other Lipid Mediators</i> , 2015, 120, 50-55.	1.0	32
170	Similar Reduction of Cholesterol-Adjusted Vitamin E Serum Levels in Simple Steatosis and Non-Alcoholic Steatohepatitis. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e113.	1.3	25
171	Reply to "The relation between flow mediated dilation and atrial fibrillation" by S. Balta. <i>International Journal of Cardiology</i> , 2015, 201, 225-226.	0.8	0
172	Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2015, 201, 513-516.	0.8	57
173	Clinical Application of NOX Activity and Other Oxidative Biomarkers in Cardiovascular Disease: A Critical Review. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 514-532.	2.5	32
174	Mediterranean diet reduces thromboxane A2 production in atrial fibrillation patients. <i>Clinical Nutrition</i> , 2015, 34, 899-903.	2.3	25
175	Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2015, 180, 1-5.	0.8	33
176	Flow-mediated dilation is associated with cardiovascular events in non-valvular atrial fibrillation patients. <i>International Journal of Cardiology</i> , 2015, 179, 139-143.	0.8	24
177	Nutritional and therapeutic approaches to modulate NADPH oxidase-derived ROS signaling in platelets.. <i>Current Pharmaceutical Design</i> , 2015, 21, 5945-5950.	0.9	5
178	Abstract 16055: Ongoing Prothrombotic State in the Early Phase of Pneumonia. <i>Circulation</i> , 2015, 132, .	1.6	0
179	New Insights into the Steen Solution Properties: Breakthrough in Antioxidant Effects via NOX2 Downregulation. <i>Oxidative Medicine and Cellular Longevity</i> , 2014, 2014, 1-10.	1.9	25
180	Epicatechin and Catechin Modulate Endothelial Activation Induced by Platelets of Patients with Peripheral Artery Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2014, 2014, 1-9.	1.9	29

#	ARTICLE	IF	CITATIONS
181	Platelet NOX, a novel target for anti-thrombotic treatment. <i>Thrombosis and Haemostasis</i> , 2014, 111, 817-823.	1.8	61
182	Total Adiponectin Is Inversely Associated with Platelet Activation and CHA ₂ DS ₂ -VASc Score in Anticoagulated Patients with Atrial Fibrillation. <i>Mediators of Inflammation</i> , 2014, 2014, 1-6.	1.4	19
183	Platelet Activation After Radiofrequency Ablation in Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 5-7.	1.6	3
184	Does Enhancement of Oxidative Stress Markers Mediate Health Effects of Ambient Air Particles?. <i>Antioxidants and Redox Signaling</i> , 2014, 21, 46-51.	2.5	13
185	Dark Chocolate Acutely Improves Walking Autonomy in Patients With Peripheral Artery Disease. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	62
186	Oxidative stress in patients affected by primary aldosteronism. <i>Journal of Hypertension</i> , 2014, 32, 2022-2029.	0.3	51
187	Different Degrees of NADPH Oxidase 2 Regulation and In Vivo Platelet Activation: Lesson From Chronic Granulomatous Disease. <i>Journal of the American Heart Association</i> , 2014, 3, e000920.	1.6	31
188	Aspirin Reload Before Elective Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 577-584.	1.4	17
189	Role of platelets in NOX2 activation mediated by TNF α in heart failure. <i>Internal and Emergency Medicine</i> , 2014, 9, 179-185.	1.0	15
190	Polyunsaturated fatty acids balance affects platelet NOX2 activity in patients with liver cirrhosis. <i>Digestive and Liver Disease</i> , 2014, 46, 632-638.	0.4	11
191	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1457-1458.	1.2	1
192	Is there a clinical role for oxidative stress biomarkers in atherosclerotic diseases?. <i>Internal and Emergency Medicine</i> , 2014, 9, 123-131.	1.0	41
193	Antioxidants for prevention of atrial fibrillation: a potentially useful future therapeutic approach? A review of the literature and meta-analysis. <i>Europace</i> , 2014, 16, 1107-1116.	0.7	47
194	Statins as Regulators of Redox Signaling in Platelets. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 1300-1312.	2.5	15
195	Platelet Activation Is Associated With Myocardial Infarction in Patients With Pneumonia. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1917-1925.	1.2	134
196	Extra virgin olive oil blunt post-prandial oxidative stress via NOX2 down-regulation. <i>Atherosclerosis</i> , 2014, 235, 649-658.	0.4	62
197	NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2014, 14, 81.	0.8	71
198	Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition. <i>Trends in Cardiovascular Medicine</i> , 2014, 24, 142-148.	2.3	34

#	ARTICLE	IF	CITATIONS
199	Is NOX2 Upregulation Implicated in Myocardial Injury in Patients with Pneumonia?. Antioxidants and Redox Signaling, 2014, 20, 2949-2954.	2.5	25
200	Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants. European Journal of Internal Medicine, 2014, 25, 566-570.	1.0	23
201	LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism. Atherosclerosis, 2014, 237, 108-116.	0.4	91
202	Mechanisms And Management Of Thrombo-Embolism In Atrial Fibrillation. Journal of Atrial Fibrillation, 2014, 7, 1112.	0.5	24
203	Abstract 16732: Urinary 11-Dehydro-Thromboxane B2 is Associated With Vascular and Non-Vascular Events in Atrial Fibrillation Patients. Circulation, 2014, 130, .	1.6	0
204	Prevalence of Peripheral Artery Disease by Abnormal Ankle-Brachial Index in Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 62, 2255-2256.	1.2	49
205	The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study. Journal of Thrombosis and Haemostasis, 2013, 11, 1053-1058.	1.9	43
206	Does NADPH Oxidase Deficiency Cause Artery Dilatation in Humans?. Antioxidants and Redox Signaling, 2013, 18, 1491-1496.	2.5	27
207	Statins as Antithrombotic Drugs. Circulation, 2013, 127, 251-257.	1.6	163
208	NOX2 up-regulation is associated with artery dysfunction in patients with peripheral artery disease. International Journal of Cardiology, 2013, 165, 184-192.	0.8	51
209	Reduced Atherosclerotic Burden in Subjects With Genetically Determined Low Oxidative Stress. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 406-412.	1.1	52
210	Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment. Atherosclerosis, 2013, 231, 392-400.	0.4	43
211	Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. International Journal of Cardiology, 2013, 168, 3241-3247.	0.8	12
212	Comment on "Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor- α -lowering property". Digestive and Liver Disease, 2013, 45, 81-82.	0.4	1
213	Letter by Violi et al Regarding Article, "Molecular Imaging of Inflammation and Platelet Adhesion in Advanced Atherosclerosis Effects of Antioxidant Therapy With NADPH Oxidase Inhibition". Circulation: Cardiovascular Imaging, 2013, 6, e3.	1.3	0
214	Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 379-388.	0.4	15
215	Vitamin E Serum Levels and Bleeding Risk in Patients Receiving Oral Anticoagulant Therapy: a Retrospective Cohort Study. Journal of the American Heart Association, 2013, 2, e000364.	1.6	36
216	Relationship Between Platelet and Urinary 8-iso-PGF2 α Levels in Subjects With Different Degrees of NOX2 Regulation. Journal of the American Heart Association, 2013, 2, e000198.	1.6	22

#	ARTICLE	IF	CITATIONS
217	Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a "real-world" community cohort of patients with atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1032-1038.	1.7	35
218	Early increase of NOX2-derived oxidative stress in children: relationship with age. <i>Pediatric Research</i> , 2013, 73, 788-793.	1.1	10
219	Different behaviour of NOX2 activation in patients with paroxysmal/persistent or permanent atrial fibrillation. <i>Heart</i> , 2012, 98, 1063-1066.	1.2	32
220	Platelet Isoprostane Overproduction in Diabetic Patients Treated With Aspirin. <i>Diabetes</i> , 2012, 61, 1626-1632.	0.3	46
221	Serum Levels of Vitamin E Are Associated With Early Recurrence of Atrial Fibrillation After Electric Cardioversion. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 327-333.	2.1	16
222	Obesity and Hypercholesterolemia are Associated with NOX2 Generated Oxidative Stress and Arterial Dysfunction. <i>Journal of Pediatrics</i> , 2012, 161, 1004-1009.	0.9	74
223	Platelet Oxidative Stress and Thrombosis. <i>Thrombosis Research</i> , 2012, 129, 378-381.	0.8	84
224	"Pitfalls in assessing platelet activation status in patients with liver disease: authors' reply". <i>Liver International</i> , 2012, , .	1.9	0
225	Pitfalls in assessing platelet activation status in patients with liver disease: authors' reply. <i>Liver International</i> , 2012, 32, 1028-1028.	1.9	0
226	Rosuvastatin reduces platelet recruitment by inhibiting NADPH oxidase activation. <i>Biochemical Pharmacology</i> , 2012, 84, 1635-1642.	2.0	33
227	Immediate Antioxidant and Antiplatelet Effect of Atorvastatin via Inhibition of Nox2. <i>Circulation</i> , 2012, 126, 92-103.	1.6	148
228	Weight loss is associated with improved endothelial dysfunction via NOX2-generated oxidative stress down-regulation in patients with the metabolic syndrome. <i>Internal and Emergency Medicine</i> , 2012, 7, 219-227.	1.0	42
229	Dark chocolate inhibits platelet isoprostanes via NOX2 down-regulation in smokers. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 125-132.	1.9	66
230	Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: A prospective multicenter cohort study. <i>American Journal of Hematology</i> , 2012, 87, 384-387.	2.0	25
231	Moderate Weight Loss Decreases Oxidative Stress and Increases Antioxidant Status in Patients with Metabolic Syndrome. <i>ISRN Obesity</i> , 2012, 2012, 1-9.	2.2	12
232	Ascorbic Acid Infusion Blunts CD40L Upregulation in Patients Undergoing Coronary Stent. <i>Cardiovascular Therapeutics</i> , 2011, 29, 385-394.	1.1	18
233	Megakaryocyte TLR2: immunity bullet?. <i>Blood</i> , 2011, 117, 5791-5792.	0.6	1
234	Effect of L-carnitine on oxidative stress and platelet activation after major surgery. <i>Acta Anaesthesiologica Scandinavica</i> , 2011, 55, 1022-1028.	0.7	23

#	ARTICLE	IF	CITATIONS
235	<sc>NADPH</sc> oxidase-mediated platelet isoprostane overproduction in cirrhotic patients: implication for platelet activation. <i>Liver International</i> , 2011, 31, 1533-1540.	1.9	37
236	Effects of resveratrol and other wine polyphenols on vascular function: an update. <i>Journal of Nutritional Biochemistry</i> , 2011, 22, 201-211.	1.9	144
237	Anoxia-Reoxygenation Enhances Platelet Thromboxane A ₂ Production via Reactive Oxygen Species-Generated NOX2. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1766-1771.	1.1	35
238	NOX2-mediated arterial dysfunction in smokers: acute effect of dark chocolate. <i>Heart</i> , 2011, 97, 1776-1781.	1.2	55
239	Inherited Human gp91 ^{phox} Deficiency Is Associated With Impaired Isoprostane Formation and Platelet Dysfunction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 423-434.	1.1	124
240	Intravenous Ascorbic Acid Infusion Improves Myocardial Perfusion Grade During Elective Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 221-229.	1.1	64
241	Nutrition, Supplements, and Vitamins in Platelet Function and Bleeding. <i>Circulation</i> , 2010, 121, 1033-1044.	1.6	73
242	Letter by Violi et al Regarding Article, "Association of Cyclooxygenase-1-Dependent and -Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization" • <i>Circulation</i> , 2010, 122, e429; author reply e430.	1.6	0
243	Atorvastatin Inhibits gp91 ^{phox} Circulating Levels in Patients With Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 360-367.	1.1	100
244	Nutraceuticals in the Early Infancy. <i>Cardiovascular Therapeutics</i> , 2010, 28, 236-245.	1.1	3
245	Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients. <i>Atherosclerosis</i> , 2010, 213, 225-234.	0.4	49
246	Role of NADPH oxidase in atherosclerosis. <i>Future Cardiology</i> , 2009, 5, 83-92.	0.5	64
247	Hereditary Deficiency of gp91 ^{phox} Is Associated With Enhanced Arterial Dilatation. <i>Circulation</i> , 2009, 120, 1616-1622.	1.6	123
248	Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 444-451.	1.9	13
249	Myeloperoxidase overexpression in children with hypercholesterolemia. <i>Atherosclerosis</i> , 2009, 205, 239-243.	0.4	18
250	Multiple anti-atherosclerotic treatments impair aspirin compliance: effects on aspirin resistance. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1832-1834.	1.9	13
251	Statins enhance circulating vitamin E. <i>International Journal of Cardiology</i> , 2008, 123, 172-174.	0.8	14
252	Oxidative Stress Is Associated With Arterial Dysfunction and Enhanced Intima-Media Thickness in Children With Hypercholesterolemia: The Potential Role of Nicotinamide-Adenine Dinucleotide Phosphate Oxidase. <i>Pediatrics</i> , 2008, 122, e648-e655.	1.0	62

#	ARTICLE	IF	CITATIONS
253	Letter by Violi and Pignatelli Regarding Article, "Effects of Random Allocation to Vitamin E Supplementation on the Occurrence of Venous Thromboembolism: Report From the Women's Health Study"; <i>Circulation</i> , 2008, 117, e312; author reply e313.	1.6	2
254	Tumour necrosis factor α upregulates platelet CD40L in patients with heart failure. <i>Cardiovascular Research</i> , 2008, 78, 515-522.	1.8	27
255	C242T Polymorphism of NADPH Oxidase p22phox and Recurrence of Cardiovascular Events in Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 752-757.	1.1	27
256	Effect of coffee drinking on platelets: inhibition of aggregation and phenols incorporation. <i>British Journal of Nutrition</i> , 2008, 100, 1276-1282.	1.2	69
257	Resveratrol, at Concentrations Attainable with Moderate Wine Consumption, Stimulates Human Platelet Nitric Oxide Production ³ . <i>Journal of Nutrition</i> , 2008, 138, 1602-1608.	1.3	133
258	Abstract 5454: Oxidative Stress is Associated with Arterial Dysfunction and Enhanced Intima-Media Thickness in Children with Hypercholesterolemia. Potential Role of Nadph Oxidase. <i>Circulation</i> , 2008, 118, .	1.6	0
259	LDL are oxidatively modified by platelets via GP91 phox and accumulate in human monocytes. <i>FASEB Journal</i> , 2007, 21, 927-934.	0.2	52
260	Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. <i>European Heart Journal</i> , 2007, 29, 54-62.	1.0	54
261	Endothelial dysfunction and peripheral arterial disease: reply. <i>European Heart Journal</i> , 2007, 28, 1910-1911.	1.0	0
262	Soluble CD40 Ligand Predicts Ischemic Stroke and Myocardial Infarction in Patients With Nonvalvular Atrial Fibrillation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2763-2768.	1.1	75
263	Early Increase of Oxidative Stress and Soluble CD40L in Children With Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1974-1981.	1.2	35
264	Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1170-1178.	1.9	57
265	Oxidative stress-mediated arterial dysfunction in patients with metabolic syndrome: Effect of ascorbic acid. <i>Free Radical Biology and Medicine</i> , 2007, 43, 853-859.	1.3	60
266	Aspirin resistance. <i>Lancet, The</i> , 2006, 367, 606-617.	6.3	503
267	Aspirin resistance. <i>Lancet, The</i> , 2006, 367, 2059-2060.	6.3	5
268	Polyphenols synergistically inhibit oxidative stress in subjects given red and white wine. <i>Atherosclerosis</i> , 2006, 188, 77-83.	0.4	171
269	Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: Effect of an antioxidant treatment. <i>Journal of Vascular Surgery</i> , 2006, 44, 525-530.	0.6	58
270	Aspirin resistance: is this term meaningful?. <i>Current Opinion in Hematology</i> , 2006, 13, 331-336.	1.2	9

#	ARTICLE	IF	CITATIONS
271	The need for a consistent definition of 'aspirin resistance'. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1618-1619.	1.9	5
272	Enhanced soluble CD40L in patients with the metabolic syndrome: relationship with in vivo thrombin generation. <i>Diabetologia</i> , 2006, 49, 1169-1174.	2.9	45
273	Oxidative-stress-mediated arterial dysfunction in patients with peripheral arterial disease. <i>European Heart Journal</i> , 2006, 28, 608-612.	1.0	105
274	Polyphenols enhance platelet nitric oxide by inhibiting protein kinase C-dependent NADPH oxidase activation: effect on platelet recruitment. <i>FASEB Journal</i> , 2006, 20, 1082-1089.	0.2	112
275	Nox2 Is Determinant for Ischemia-Induced Oxidative Stress and Arterial Vasodilatation: A Pilot Study in Patients With Hereditary Nox2 Deficiency. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, e131-2.	1.1	31
276	Alpha-Linolenic Acid-Rich Wheat Germ Oil Decreases Oxidative Stress and CD40 Ligand in Patients With Mild Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2577-2578.	1.1	53
277	Tumor necrosis factor- α as trigger of platelet activation in patients with heart failure. <i>Blood</i> , 2005, 106, 1992-1994.	0.6	94
278	Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2784-2789.	1.9	70
279	Vitamin C inhibits platelet expression of CD40 ligand. <i>Free Radical Biology and Medicine</i> , 2005, 38, 1662-1666.	1.3	40
280	Early Anticoagulant Effect of Atorvastatin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, e145; author reply e145-6.	1.1	0
281	Short-Term Treatment With Atorvastatin Reduces Platelet CD40 Ligand and Thrombin Generation in Hypercholesterolemic Patients. <i>Circulation</i> , 2005, 111, 412-419.	1.6	159
282	CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2005, 45, 35-42.	1.2	56
283	The polyphenols quercetin and catechin synergize in inhibiting platelet CD40L expression. <i>Thrombosis and Haemostasis</i> , 2005, 94, 888-889.	1.8	15
284	gp91phox-Dependent Expression of Platelet CD40 Ligand. <i>Circulation</i> , 2004, 110, 1326-1329.	1.6	137
285	Aspirin. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 338-339.	1.9	4
286	Aspirin. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 335-336.	1.9	6
287	Vitamin E for the Treatment of Cardiovascular Disease: Is There a Future?. <i>Annals of the New York Academy of Sciences</i> , 2004, 1031, 292-304.	1.8	25
288	Soluble CD154 plasma levels in patients with systemic lupus erythematosus: Modulation by antiphospholipid antibodies. <i>Arthritis and Rheumatism</i> , 2004, 50, 1693-1694.	6.7	15

#	ARTICLE	IF	CITATIONS
289	Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. <i>Journal of the American College of Cardiology</i> , 2004, 43, 979-984.	1.2	130
290	Enhanced platelet release of superoxide anion in systemic hypertension. <i>Journal of Hypertension</i> , 2004, 22, 1151-1156.	0.3	37
291	Enhanced TNF α and oxidative stress in patients with heart failure: effect of TNF α on platelet O ₂ - production. <i>Thrombosis and Haemostasis</i> , 2003, 90, 317-325.	1.8	58
292	Red and white wine differently affect collagen-induced platelet aggregation. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2002, 32, 356-358.	0.5	25
293	Increased Superoxide Anion Production by Platelets in Hypercholesterolemic Patients. <i>Thrombosis and Haemostasis</i> , 2002, 87, 796-801.	1.8	46
294	Involvement of GD3 in platelet activation. A novel association with Fc γ receptor. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2002, 1583, 297-304.	1.2	21
295	Metformin decreases platelet superoxide anion production in diabetic patients. <i>Diabetes/Metabolism Research and Reviews</i> , 2002, 18, 156-159.	1.7	54
296	Vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated platelets. <i>Haematologica</i> , 2002, 87, 420-6.	1.7	20
297	Increased superoxide anion production by platelets in hypercholesterolemic patients. <i>Thrombosis and Haemostasis</i> , 2002, 87, 796-801.	1.8	7
298	Involvement of the glycoprotein Ib-V-IX complex in nickel-induced platelet activation.. <i>Environmental Health Perspectives</i> , 2001, 109, 225-228.	2.8	4
299	The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide. <i>American Journal of Clinical Nutrition</i> , 2000, 72, 1150-1155.	2.2	244
300	Superoxide Anion and Hydroxyl Radical Release by Collagen-induced Platelet Aggregation - Role of Arachidonic Acid Metabolism. <i>Thrombosis and Haemostasis</i> , 2000, 83, 485-490.	1.8	90
301	Vitamin E Inhibits Collagen-Induced Platelet Activation by Blunting Hydrogen Peroxide. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 2542-2547.	1.1	46
302	Concomitant activation of G β protein-coupled receptor and protein kinase C or phospholipase C is required for platelet aggregation. <i>FEBS Letters</i> , 1999, 460, 37-40.	1.3	17
303	Platelet Hyperactivity in Hypertensive Older Patients Is Controlled by Lowering Blood Pressure. <i>Journal of the American Geriatrics Society</i> , 1999, 47, 943-947.	1.3	26
304	Concomitant activation of G α protein-coupled receptors does not require an increase in cytosolic calcium for platelet aggregation. <i>FEBS Letters</i> , 1998, 435, 115-118.	1.3	17
305	Effects on platelet function of combination etoposide and carboplatin chemotherapy in pediatric oncology patients. <i>Platelets</i> , 1998, 9, 309-314.	1.1	4
306	Hydrogen Peroxide Is Involved in Collagen-Induced Platelet Activation. <i>Blood</i> , 1998, 91, 484-490.	0.6	278

#	ARTICLE	IF	CITATIONS
307	Nickel Enhances Collagen-induced Platelet Activation Acting by Increasing the Organization of the Cytoskeleton. <i>Thrombosis and Haemostasis</i> , 1998, 79, 395-399.	1.8	7
308	Hydrogen Peroxide Is Involved in Collagen-Induced Platelet Activation. <i>Blood</i> , 1998, 91, 484-490.	0.6	8
309	MECHANISM OF THE PERSISTING TxA ₂ RECEPTOR ANTAGONISM BY PICOTAMIDE. <i>Thrombosis Research</i> , 1997, 85, 207-215.	0.8	10
310	Platelet Activation by Superoxide Anion and Hydroxyl Radicals Intrinsically Generated by Platelets That Had Undergone Anoxia and Then Reoxygenated. <i>Circulation</i> , 1997, 95, 885-891.	1.6	126
311	Effects of storage on in vitro platelet responses: Comparison of ACD and Na citrate anticoagulated samples. , 1996, 10, 134-139.		10
312	Acid citrate dextrose (acd) formula a as a new anticoagulant in the measurement of in vitro platelet aggregation. <i>Journal of Clinical Laboratory Analysis</i> , 1995, 9, 138-140.	0.9	22
313	Effect of picotamide on the calcium mobilization and phospholipase C activation in human platelets. <i>Thrombosis Research</i> , 1994, 74, 453-461.	0.8	8